Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Advances in Therapy
|
March 14, 2022
Prescription Market Share and Treatment Patterns in Atopic Dermatitis: A Retrospective Observational Study Using US Insurance Claims
Christian Fenske, Natalie Boytsov, Jiaying Guo, et al.
Journal of Vascular Surgery
|
July 1, 2019
Results from a prospective multicenter feasibility study of Zenith p-Branch stent graft
Mark A Farber, Gustavo S Oderich, Carlos Timaran, et al.
Journal of Cutaneous Medicine and Surgery
|
January 28, 2022
Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)
David Rosmarin, Marta Casillas, Sherry Chen, et al.
The Journal of Dermatological Treatment
|
April 12, 2023
Burden of adult atopic dermatitis and unmet needs with existing therapies
Elizabeth D Bacci, Julia R Correll, Evangeline J Pierce, et al.
Journal of Cutaneous Medicine and Surgery
|
March 31, 2022
Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study
David Rosmarin, Scott Fretzin, Lindsay Strowd, et al.
The Journal of Dermatological Treatment
|
April 28, 2024
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Jennifer Soung, Sonja Ständer, Jan Gutermuth, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
December 23, 2025
Lebrikizumab is Efficacious in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Regardless of Atopic Comorbidities
Ellen R Sher, Alexandra Golant, Marjolein de Bruin-Weller, et al.
Dermatology and Therapy
|
June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
Peter A Lio, April Armstrong, Jan Gutermuth, et al.
The Journal of Dermatological Treatment
|
May 12, 2024
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Adelaide A Hebert, Carsten Flohr, H Chih-Ho Hong, et al.
The Journal of Dermatological Treatment
|
September 25, 2024
Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry
Jonathan I Silverberg, Linda Stein Gold, Seemal Desai, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Advances in Therapy
|
March 14, 2022
Prescription Market Share and Treatment Patterns in Atopic Dermatitis: A Retrospective Observational Study Using US Insurance Claims
Christian Fenske, Natalie Boytsov, Jiaying Guo, et al.
Journal of Vascular Surgery
|
July 1, 2019
Results from a prospective multicenter feasibility study of Zenith p-Branch stent graft
Mark A Farber, Gustavo S Oderich, Carlos Timaran, et al.
Journal of Cutaneous Medicine and Surgery
|
January 28, 2022
Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)
David Rosmarin, Marta Casillas, Sherry Chen, et al.
The Journal of Dermatological Treatment
|
April 12, 2023
Burden of adult atopic dermatitis and unmet needs with existing therapies
Elizabeth D Bacci, Julia R Correll, Evangeline J Pierce, et al.
Journal of Cutaneous Medicine and Surgery
|
March 31, 2022
Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study
David Rosmarin, Scott Fretzin, Lindsay Strowd, et al.
The Journal of Dermatological Treatment
|
April 28, 2024
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Jennifer Soung, Sonja Ständer, Jan Gutermuth, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
December 23, 2025
Lebrikizumab is Efficacious in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Regardless of Atopic Comorbidities
Ellen R Sher, Alexandra Golant, Marjolein de Bruin-Weller, et al.
Dermatology and Therapy
|
June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
Peter A Lio, April Armstrong, Jan Gutermuth, et al.
The Journal of Dermatological Treatment
|
May 12, 2024
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Adelaide A Hebert, Carsten Flohr, H Chih-Ho Hong, et al.
The Journal of Dermatological Treatment
|
September 25, 2024
Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry
Jonathan I Silverberg, Linda Stein Gold, Seemal Desai, et al.
Page
of 2